Art. -Nr.: HY-N6949

Juglone

(Synonyms: 5-Hydroxy-1,4-naphthalenedione)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Juglone (5-hydroxy-1,4-naphthalenedione) is a yellow dye that can be extracted from Juglans regia. Juglone induces apoptosis through the mitochondrial pathway. Juglone has antibacterial and antitumor activity .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 481-39-0
Formel: C₁₀H₆O₃
Molecular Weight:174.16

Speicherung:

4°C, protect from light

* The compound is unstable in solutions, freshly prepared is recommended.

Juglone Chemical Structure

CAS. Nr.: 481-39-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	64 μM Compound: 6	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A2780	IC₅₀	1.4 μM Compound: 14	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A549	IC₅₀	11.87 μM Compound: 7; JUG	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
A549	IC₅₀	7 μM Compound: 1	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
B16-F10	IC₅₀	6 μM Compound: 1	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
BT-549	GI₅₀	>100 μM Compound: 4	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
CAL-51	GI₅₀	>100 μM Compound: 4	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
DU-145	IC₅₀	11.67 μM Compound: Juglone	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
EA.hy 926	IC₅₀	5.57 μM Compound: 7; JUG	Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
HaCaT	IC₅₀	0.8 μM Compound: 7d ; Juglone	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]
HBL-100	GI₅₀	66 μM Compound: 6	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HCC1954	GI₅₀	6.44 μM Compound: 4	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	GI₅₀	4.2 μM Compound: 4	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	IC₅₀	31.6 μM Compound: Junglone	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
HEK293	EC₅₀	1.7 μM Compound: 5	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HeLa	GI₅₀	89 μM Compound: 6	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HeLa	IC₅₀	13 μM Compound: 14	Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells	[PMID: 19028102]
HeLa	IC₅₀	15.73 μM Compound: 3	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 33766765]
HeLa	IC₅₀	65.46 μM Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 24631733]
HeLa	IC₅₀	68.46 μM Compound: 12	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 24631733]
HeLa	IC₅₀	93.7 μM Compound: 1a	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	93.7 μM Compound: 44	Antitumor activity against human HeLa cells assessed as cell growth inhibition Antitumor activity against human HeLa cells assessed as cell growth inhibition	[PMID: 36858050]
HepG2	IC₅₀	20.43 μM Compound: Juglone	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated upto 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated upto 48 hrs by MTT assay	[PMID: 38458106]
Hs 683	IC₅₀	7 μM Compound: 1	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
HT-29	IC₅₀	>100 μM Compound: 1a	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	>100 μM Compound: 44	Antitumor activity against human HT-29 cells assessed as cell growth inhibition Antitumor activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36858050]
HT-29	IC₅₀	7.71 μM Compound: Juglone	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
J774.2	IC₅₀	13.36 μM Compound: Junglone	Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774.2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
K562	GI₅₀	>100 μM Compound: 4	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
KB	IC₅₀	6.55 μM Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 33766765]
KB 3-1	IC₅₀	26.4 μM Compound: Junglone	Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37001390]
LNCaP	IC₅₀	13.8 μM Compound: Juglone	Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 23643730]
MCF7	GI₅₀	32.6 μM Compound: 4	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MCF7	IC₅₀	13 μM Compound: 1	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
MCF7	IC₅₀	16.5 μM Compound: 1a	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	16.5 μM Compound: 44	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	6.15 μM Compound: 7; JUG	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
MDA-MB-231	IC₅₀	7.15 μM Compound: Juglone	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
MDA-MB-231	IC₅₀	75.7 μM Compound: 44	Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	75.76 μM Compound: 1a	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-453	IC₅₀	27.5 μM Compound: 44	Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-453	IC₅₀	27.52 μM Compound: 1a	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	65.4 μM Compound: 1a	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	65.4 μM Compound: 44	Antitumor activity against human ME-180 cells assessed as cell growth inhibition Antitumor activity against human ME-180 cells assessed as cell growth inhibition	[PMID: 36858050]
MOLM-13	GI₅₀	21.9 μM Compound: 4	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MV4-11	GI₅₀	0.06 μM Compound: 4	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
PC-3	GI₅₀	4.77 μM Compound: Juglone	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 28838831]
PC-3	GI₅₀	4.77 μM Compound: Juglone	Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay	[PMID: 30153964]
PC-3	IC₅₀	88.7 μM Compound: 1a	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	88.7 μM Compound: 44	Antitumor activity against human PC-3 cells assessed as cell growth inhibition Antitumor activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36858050]
Platelet	IC₅₀	1.18 μM Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
Platelet	IC₅₀	4.45 μM Compound: 7; JUG	Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis Antiplatelet activity in human platelets assessed as inhibition of U46619-induced platelet aggregation by turbidimetric analysis	[PMID: 38381886]
RPMI-8226	IC₅₀	3.95 μM Compound: 7; JUG	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
SK-MEL-28	IC₅₀	7 μM Compound: 1	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
SW1573	GI₅₀	50 μM Compound: 6	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
T47D	GI₅₀	77 μM Compound: 6	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
U-373MG ATCC	IC₅₀	17 μM Compound: 1	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
U-87MG ATCC	IC₅₀	7.45 μM Compound: 7; JUG	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
WiDr	GI₅₀	81 μM Compound: 6	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]

In Vitro

Juglone (0-500 μg/mL, 15 h) shows significant antibacterial activity against Staphylococcus aureus, with MIC values ranging from 64-512 μg/mL^[1].
Juglone(5-20 μM, 24 h) induces apoptosis of SGC-7901 cells through the mitochondrial pathway mediated by ROS production and the decrease of Bcl-2/Bax ratio^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay ^[2]

Cell Line:

SGC-7901
Concentration:

5, 10, 15, 20 μM
Incubation Time:

24 h
Result:

Inhibited cell growth in a dose-dependent manner.

Apoptosis Analysis ^[2]

Cell Line:

SGC-7901
Concentration:

5, 10, 15, 20 μM
Incubation Time:

24 h
Result:

Increased the number of early apoptotic cells.

Western Blot Analysis ^[2]

Cell Line:

SGC-7901
Concentration:

5, 10, 15, 20 μM
Incubation Time:

24 h
Result:

Decreased the expression of Bcl-2 and increased the Bax protein.

In Vivo

Juglone (0.25 or 1 mg/kg, oral, 70 days) prevents metabolic endotoxemia-nduced hepatitis and neuroinflammation by inhibiting TLR4/NF-kB signaling pathway in high-fat diet rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

High-fat diet rats model^[3]
Dosage:

0.25 or 1 mg/kg
Administration:

p.o. for 70 days
Result:

Regulated the expression of s TNF-α, IL-1β and IL-6.
Inhibited the TLR4 expression and NF-kappa activity.

Chemical Information

CAS. Nr. 481-39-0
Appearance Solid
Molecular Weight 174.16
Formel C₁₀H₆O₃
Color Brown to orange
SMILES

O=C(C1=C2C=CC=C1O)C=CC2=O
Synonyms

5-Hydroxy-1,4-naphthalenedione
Structure Classification
- Quinones
- Naphthalene Quinones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (4)

All

Sort by:

Journal Impact Factor

Phytomedicine

Juglone promotes spinal cord injury recovery by suppressing pyroptosis and necroptosis through FOS/USP53/ubiquitination. [Abstract]

2025 Sep 27:148:157341. PMID: 41045624
Int J Biol Macromol

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. [Abstract]

2021 Jul 31:183:182-192. PMID: 33901557
Biochem Pharmacol

Juglone targets MMP-1 to inhibit gastric cancer progression. [Abstract]

2025 Aug 28;242(Pt 2):117289. PMID: 40885322
J Tradit Chinese Medical Sci

31 July 2022.

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : ≥ 3.33 mg/mL (19.12 mM; DMSO can inactivate Juglone's activity)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.7418 mL

28.7092 mL

57.4185 mL

5 mM

1.1484 mL

5.7418 mL

11.4837 mL

10 mM

0.5742 mL

2.8709 mL

5.7418 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 0.33 mg/mL (1.89 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (3.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zmantar T, et al. Use of juglone as antibacterial and potential efflux pump inhibitors in Staphylococcus aureus isolated from the oral cavity. Microb Pathog. 2016 Dec;101:44-49. [Content Brief]

[2]. Ji YB, et al. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol. 2011 Jan;63(1-2):69-78. [Content Brief]

[3]. Peng X, et al. Juglone prevents metabolic endotoxemia-induced hepatitis and neuroinflammation via suppressing TLR4/NF-κB signaling pathway in high-fat diet rats. Biochem Biophys Res Commun. 2015 Jul 3;462(3):245-50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol	1 mM	5.7418 mL	28.7092 mL	57.4185 mL	143.5462 mL
	5 mM	1.1484 mL	5.7418 mL	11.4837 mL	28.7092 mL
	10 mM	0.5742 mL	2.8709 mL	5.7418 mL	14.3546 mL
	15 mM	0.3828 mL	1.9139 mL	3.8279 mL	9.5697 mL

Keywords

Juglone

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Juglone

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Juglone

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Juglone

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Juglone

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Juglone Related Classifications

HY-N6949 Related Classifications